Prostate Cancer Studies Currently Recruiting Participants at the University of Chicago Medicine Comprehensive Cancer Center

Study Number Title
IRB13-0756 Quantitative DCEMRI of Prostate Cancer Correlation with Gold Standards
Select
10-487-A The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
Select
IRB14-0081 Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Select
IRB15-0091 An Open-label, Dose-escalation/expansion, Phase 1 Study of ASP4132, Given Orally to Subjects with Advanced Refractory Solid Tumors and Lymphoma
12803B Quality of Life after Radical Prostatectomy
10-174-B Feasibility of Collection & Analysis of Circulating and Disseminated Tumor Cells from men with Advanced Prostate Cancer
14934A Radiotherapy for Prostate Cancer: Dosimetric and Clinical Outcomes in the IMRT Era
12278A Clinical Urology Research Screening Protocol
Select
10-625-A A feasibility study of oral hormonal therapy and radiation for non-metastatic, intermediate or high risk prostate cancer in men 70 and older or with medical comorbidities
11-0061 Evaluation of endorectal MRI for risk stratification, treatment planning, and workup after biochemical failure in patients with adenocarcinoma of the prostate
Select
CIRB14-0811 NRG-BR001: Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
Select
CIRB15-1008 A031102: A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
Select
12-2086 The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men with Biochemically Relapsed Hormone Sensitive Prostate Cancer
Select
IRB13-0774 Randomized Phase II Trial of Paclitaxel, Ifosfamide and Cisplatin (TIP) vs. Bleomycin, Etoposide and Cisplatin (BEP) for Patients with Previously Untreated Intermediate and Poor-Risk Germ Cell Tumors
Select
IRB13-0979 A Phase I/II Trial of Enzalutamide plus the Glucocorticoid Receptor Antagonist Mifepristone for Patients with Metastatic Castration Resistant Prostate Cancer (CRPC)
Select
IRB15-0496 A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer: The TRANSFORMER Trial (Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance)
Select
IRB13-0692 A Phase II Study of Recombinant Glycosylated Human Interluekin-7 (CYT 107) after Completion of Standard FDA Approved Therapy with Sipuleugel-T (Provenge) for Patients with Asyptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Select
IRB14-1543 Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy
Select
11-0709 A Prospective Randomized Pilot Study Evaluating the Food Effect on the Pharmacokinetics and Pharmacodynamics of Abiraterone Acetate in Men with Castrate Resistant Prostate Cancer

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.
Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT team